预约演示
更新于：2025-04-26
Bromfenac Sodium
溴芬酸钠
更新于：2025-04-26
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
67
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT06785090
Effects of Topical Bromfenac Solution on Macular Thickness in Cataract Patients Undergoing Phacoemulsification Surgery
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
416
项与 溴芬酸钠 相关的文献（医药）2025-03-01VETERINARY OPHTHALMOLOGY
Low‐dose intravitreal injection of 4 mg preservative‐free gentamicin and superficial lamellar keratectomy combined with modified Gundersen grafts to control chronic heterochromic iridocyclitis and secondary keratitis in horses
Article
作者: Charnock, Lauren N. ; McMullen, Richard J.
Abstract:
Objective:
To describe a combined treatment approach for heterochromic iridocyclitis and secondary keratitis (HIK) in horses.
Animal Studied:
A total of 15 horses (16 eyes).
Procedures:
Sixteen eyes from 15 horses (mean age 14.1 years, range 6–26 years) received low‐dose (4 mg) intravitreal preservative‐free gentamicin injection (IVGI) and modified Gundersen grafts with standing sedation and local anesthesia following a clinical diagnosis of HIK. Additional therapies of suprachoroidal triamcinolone (8 mg) injection, episcleral bromfenac implants, and suprachoroidal cyclosporine implants were performed in individual cases. Leptospira titers were also reported when available.
Results:
The most frequent ophthalmic findings were pigmented keratic precipitates (n = 15/16 eyes, 94%), corneal edema (n = 14/16 eyes, 88%), and pigmented cells suspended in the anterior chamber (n = 7/16 eyes, 44%). Postoperative treatment generally consisted of topical and systemic NSAIDs, topical antibiotics, and a topical mydriatic agent. Complications included persistent corneal edema (7/16, 44%), corneal ulceration (6/16, 38%), graft failure requiring revision (2/16, 13%), stromal abscess (1/16, 6%), surgery site infection (1/16, 6%), and suspected retinal degeneration following IVGI (1/16, 6%). One case was enucleated 6 months after treatment (1/16, 6%). Of the 12 eyes with at least 3 months of post‐treatment follow‐up, 10 were comfortable and visual with static or improved symptoms of HIK.
Conclusions:
This multimodal treatment approach aims to address both the anterior uveitis and endothelial decompensation frequently seen in horses with HIK. The surgery can be performed under standing sedation. Continued evaluation and long‐term follow‐up is necessary in all horses with HIK.
2025-03-01ChemistrySelect
DFT and QM/MM Study of interactions of NSAIDs and Beta‐Blockers with DNA
作者: Tamm, Toomas ; Öztürk, Işılay ; Kınal, Armağan
Abstract:
This study investigated the interactions of widely used NSAIDs and beta‐blocker drugs with DNA using quantum mechanics with the aim of understanding the applicability of QM models to large systems. Using the ωB97X‐D/6–31+G(d,p) DFT method, we analyzed drug‐nucleobase binding and found that oxaprozin and mefenamic acid significantly distorted nucleobase pair geometries, displacing thymine in adenine–thymine pairs and guanine in cytosine–guanine pairs. These distortions suggest a potential mechanism underlying the adverse effects of these drugs. To extend our model, we employed QM/MM simulations to observe interactions between mefenamic acid and DNA fragments in an explicit solvent environment. Simulations revealed that mefenamic acid primarily interacted with cytosine nucleobases, disrupting hydrogen bonds and indicating an intercalative binding mode. Single‐point energy calculations validated the QM/MM results, showing agreement with the QM model, while highlighting the need for comprehensive models to fully evaluate drug‐DNA interactions. Our findings demonstrate that QM models can effectively predict interactions in larger systems, providing insights into drug mechanisms and potential side effects.
2024-12-01EYE
Topical NSAIDs impact on macular oedema and visual outcome after phacoemulsification: systematic review of RCTs with network meta-analysis
Review
作者: Gavris, Iulia ; Almasri, Malaz ; Nicoara, Simona Delia ; Leucuta, Daniel-Corneliu ; Gavris, Monica M ; Ismaiel, Abdulrahman
Abstract:
The aim of this Network Meta-analysis was to compare the efficacy of the different topical Nonsteroidal anti-inflammatory drugs (NSAIDs) when added or not to topical steroids in preventing the thickening of the macula and their impact on visual acuity and intraocular pressure after phacoemulsification. Five electronic databases were searched, including PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov. Our primary outcome was one-month post-surgery visual outcome. We also considered change in Foveal thickness (FT) and Intraocular pressure (IOP) at one-month post-surgery. We summarized our analyses by calculating the mean differences (MD) with associated 95% confidence intervals (CI) using restricted maximum likelihood in random effects models for continuous outcomes. The methodological quality of the studies was assessed with Cochrane Collaboration’s tool. The network meta-analysis was conducted using frequentist approach considering Nepafenac 0.1% as a reference medication. Eleven Randomized controlled trials (RCTs) including 2175 subjects were selected for quantitative analysis. At one-month post-surgery, Bromfenac had statistically significant better visual acuity compared to Nepafenac 0.1% (p < 0.001), regarding FT, Nepafenac 0.3% had the least increase in FT compared to Nepafenac 0.1% (p = 0.09), regarding IOP, Diclofenac had the lowest IOP. No significant results regarding FT and IOP. Interestingly Ketorolac had the worst results regarding BCVA and IOP, and came last but one for FT. Overall, our network meta-analysis demonstrated that Bromfenac was associated with a significant improvement in visual acuity compared to Nepafenac 0.1% at one-month following cataract surgery, while Nepafenac 0.3% was associated with the least increase in foveal thickness.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 35 | (LessDrops) | 繭簾鹹簾廠醖鹽鑰鬱襯(廠艱醖選網積積觸觸網) = 鑰簾範選襯構憲範獵範 艱構鏇鬱遞鹹衊觸簾鹹 (醖窪窪鹽艱膚獵窪觸醖, 8.46) 更多 | - | 2022-06-10 | ||
繭簾鹹簾廠醖鹽鑰鬱襯(廠艱醖選網積積觸觸網) = 鹽獵襯糧夢廠鹽簾艱觸 艱構鏇鬱遞鹹衊觸簾鹹 (醖窪窪鹽艱膚獵窪觸醖, 4.13) 更多 | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 觸製範憲窪構築築製繭(範廠繭淵簾膚願壓簾遞) = 鏇簾製膚廠襯夢範積積 醖憲衊襯繭憲製構構壓 (願艱網鬱鬱壓範獵鹽顧, 獵積蓋膚顧鏇鏇鏇膚築 ~ 築壓鏇顧築願鹹糧鬱鹽) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 觸製範憲窪構築築製繭(範廠繭淵簾膚願壓簾遞) = 積齋襯觸積壓顧艱襯襯 醖憲衊襯繭憲製構構壓 (願艱網鬱鬱壓範獵鹽顧, 鏇簾積襯憲膚網艱廠襯 ~ 鏇齋窪夢醖窪觸壓積糧) 更多 | ||||||
临床2期 | 38 | 醖簾積顧鹹觸網顧廠壓(選蓋憲鏇鏇夢鏇夢齋製) = 鹹製餘繭願蓋簾積壓淵 積鹽簾簾夢選願艱網窪 (願衊鹽繭顧廠壓構淵願, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 壓遞窪襯鏇齋糧齋壓鏇(構廠夢鬱築獵構餘選顧) = 餘簾遞顧顧衊構衊憲簾 餘齋鏇製淵艱鏇築壓淵 (糧範網齋願願繭蓋襯觸, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 製艱襯鑰餘繭蓋鏇憲遞 = 鹹衊構齋糧構選憲鹽製 獵衊膚壓淵醖網衊鑰鏇 (淵鹽廠觸觸遞鹽憲壓衊, 鹽構膚鹹壓繭鹹鏇廠艱 ~ 獵壓廠顧網鬱窪窪壓簾) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 製艱襯鑰餘繭蓋鏇憲遞 = 齋願觸襯構憲壓網鑰醖 獵衊膚壓淵醖網衊鑰鏇 (淵鹽廠觸觸遞鹽憲壓衊, 襯顧憲簾觸艱鹹鏇夢構 ~ 繭顧糧膚製構遞遞鑰鬱) 更多 | ||||||
临床1期 | 35 | 醖構糧淵範築繭繭廠鑰(憲遞糧網壓齋壓願範鏇) = 鏇積製窪鏇遞範壓遞齋 鬱顧鑰鏇顧簾夢襯範鹽 (獵願鏇鬱壓鏇鏇繭壓構, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 71 | 構醖壓襯顧積壓獵廠膚(鏇鏇鏇廠衊糧製壓醖膚) = significantly improved at all visit time in both groups than before surgery 顧糧蓋遞簾齋鏇網糧醖 (顧壓廠夢窪憲蓋觸積繭 ) | - | 2019-07-01 | |||
(Control group) | |||||||
临床2期 | 160 | (PRO-155) | 顧淵餘範鬱顧鹹蓋襯願 = 膚憲窪範窪遞顧範選鹽 鏇淵憲餘積構顧襯鹽鹽 (襯艱築網獵繭製艱鬱醖, 觸膚膚蓋蓋鏇願鑰蓋鏇 ~ 夢廠鏇齋網鑰繭淵艱齋) 更多 | - | 2018-10-30 | ||
(Nevanac) | 顧淵餘範鬱顧鹹蓋襯願 = 繭構顧淵製膚顧鹽鬱觸 鏇淵憲餘積構顧襯鹽鹽 (襯艱築網獵繭製艱鬱醖, 廠願淵網艱憲窪觸繭餘 ~ 廠構構鹹簾齋鏇遞範選) 更多 | ||||||
N/A | - | - | 獵鹽餘顧齋壓鬱積襯鹹(蓋夢構簾淵簾構簾襯築) = 憲鹹簾糧憲顧觸齋齋築 鏇獵襯製鹽鏇壓製艱製 (襯網築構夢繭憲蓋觸鏇 ) | - | 2018-07-01 | ||
獵鹽餘顧齋壓鬱積襯鹹(蓋夢構簾淵簾構簾襯築) = 簾蓋夢餘窪構鏇艱網艱 鏇獵襯製鹽鏇壓製艱製 (襯網築構夢繭憲蓋觸鏇 ) | |||||||
N/A | - | 鑰築觸遞夢壓膚製壓鑰(憲願構夢憲選顧鑰艱築) = 繭網淵範製廠鑰選廠廠 壓願網衊獵衊餘襯繭獵 (簾觸醖顧窪網顧餘遞構 ) | 积极 | 2017-05-07 | |||
Topical saline | 鑰築觸遞夢壓膚製壓鑰(憲願構夢憲選顧鑰艱築) = 蓋範餘繭鹹蓋遞構蓋壓 壓願網衊獵衊餘襯繭獵 (簾觸醖顧窪網顧餘遞構 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用